1. Scrip

Melinta To Launch First Commercial Drug Baxdela Independently

 
• By Jessica Merrill

Melinta is positioning its novel fluroquinolone antibiotic as an attractive option for seriously ill patients with underlying chronic conditions, but Baxdela will face challenges in a market dominated by generics.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.

Melinta Therapeutics Inc. will sell its first commercial drug – the antibiotic Baxdela (delafloxacin) – independently through a hospital-based commercial organization that is in the process of being built, according to CEO Eugene Sun.

FDA approved the fluoroquinolone antibiotic June 19 for the treatment of acute bacterial skin and skin structure infections (ABSSI) in both an intravenous and oral

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip